title: Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.
abstract: The most common and leading cause of cancer-related death in men is lung cancer. Despite the recent advances in chemotherapy, advanced lung cancer still remains incurable. For this, the understanding of molecular mechanisms involved in lung carcinogenesis is necessary to provide potentially effective therapeutic targets for the treatment of lung cancer, and thus the therapeutic limitations can be overcome. Cyclooxygenase-2 (COX-2) is an important inflammation factor that is reported to be up-regulated in different cancers. A number of COX-2 inhibitors have been developed, but most of them are restricted due to the different risk factors. Currently, the FDA has allowed celecoxib to remain on the market but advised physicians to apply this drug with alternative therapies or to use at a low dosage. Some other COX-2 inhibitors, such as, apricoxib and etoricoxib are under critical investigation currently. Celecoxib is being tested in clinical trials against lung cancer, as a single agent or in combination with other agents. Recent studies have suggested celecoxib as a feasible and clinically active regimen in the treatment of patients with lung cancer. However, more clinical trials are necessary for the better understanding of the role of selective COX-2 inhibitors in the prevention and treatment of lung cancer along with their assessment of toxicity. In this review, we have discussed the mechanism of actions of COX-2 in cancer progression and the therapeutic use of COX-2 inhibitors in the treatment of lung cancer with subsequent clinical studies and future management.
authors.affiliation: Xiangya Hospital of Central South University, Changsha 410008, PR China; School of Pharmaceutical Sciences, Central South University, Changsha 410013, PR China. Electronic address: 731948949@qq.com.
authors.forename: Rui
authors.initials: R
authors.lastname: Liu
authors.affiliation: School of Pharmaceutical Sciences, Central South University, Changsha 410013, PR China. Electronic address: xukp376@aliyun.com.
authors.forename: Kang-Ping
authors.initials: KP
authors.lastname: Xu
authors.affiliation: Xiangya Hospital of Central South University, Changsha 410008, PR China; School of Pharmaceutical Sciences, Central South University, Changsha 410013, PR China. Electronic address: tgs395@csu.edu.cn.
authors.forename: Gui-Shan
authors.initials: GS
authors.lastname: Tan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000068579:Celecoxib / Q000494:pharmacology / Q000627:therapeutic use; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D051546:Cyclooxygenase 2; D000068579:Celecoxib
keywords: Celecoxib; Clinical trials; Combination therapy; Cyclooxygenase-2; Lung cancer